Confluence of Epidemics of Hepatitis C, Diabetes, Obesity, and Chronic Kidney Disease in the United States Population

被引:33
作者
Lazo, Mariana [1 ,2 ]
Nwankwo, Chizoba [3 ]
Daya, Natalie R. [2 ]
Thomas, David L. [4 ]
Mehta, Shruti H. [2 ]
Juraschek, Stephen [1 ,2 ]
Willis, Kerry [5 ]
Selvin, Elizabeth [1 ,2 ]
机构
[1] Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[3] Merck & Co Inc, Whitehouse Stn, Kenilworth, NJ USA
[4] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA
[5] Natl Kidney Fdn, New York, NY USA
基金
美国国家卫生研究院;
关键词
Viral Hepatitis; Epidemiology; Complications; Risk Factors; 3RD NATIONAL-HEALTH; VIRUS-INFECTION; INSULIN-RESISTANCE; PREVALENCE; STEATOSIS; FIBROSIS; IMPACT; ASSOCIATION; LEDIPASVIR; SOFOSBUVIR;
D O I
10.1016/j.cgh.2017.04.046
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Obesity, kidney disease, and diabetes are common conditions that can affect outcomes of patients with chronic hepatitis C. The authors aimed to quantify the burden of these comorbid conditions among adults with chronic hepatitis C in the United States and to estimate the risk of death among people with chronic hepatitis C and comorbidities. METHODS: The authors conducted cross-sectional and prospective analyses of 13,726 participants in the third National Health and Nutrition Examination Survey (NHANES III) and 23,691 participants of NHANES 1999-2012. Serum samples were analyzed for the presence of antibodies to hepatitis C virus (anti-HCV); in samples found to be positive for anti-HCV, the authors quantified HCV RNA (viral load). Individuals with anti-HCV and detectable HCV RNA were considered to have chronic hepatitis C. Comorbidities were defined using self-reported, physical examination, and laboratory data, as available. The authors used logistic models and predictive margins to estimate the adjusted prevalence of comorbidities in patients with chronic hepatitis C. The authors used Poisson regression models to estimate adjusted mortality rates based on chronic hepatitis C status, with or without comorbidities. Cox proportional hazards regression models to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of all-cause, cardiovascular, and cancer mortality according to chronic hepatitis C status, with and without comorbidities. RESULTS: Among persons with chronic hepatitis C, the demographic-adjusted prevalence estimate of diabetes was 17.9% (95% CI, 11.2%-27.5%) and of obesity was 20.9% (95% CI, 12.4%-29.5%). Overall, 69.6% of persons with chronic hepatitis C had at least 1 major cardiometabolic comorbidity (95% CI, 62.1%-76.2%). Only 38% of adults with chronic hepatitis C reported a diagnosis of liver disease. Chronic hepatitis C was associated with a substantially increased risk of death (HR, 2.45), especially in the presence of diabetes (HR, 3.24) or chronic kidney disease (HR, 4.39). CONCLUSION: In an analysis of NHANES data, the authors found that individuals with chronic hepatitis C have a high burden of major cardiometabolic comorbidities. Diabetes and chronic kidney disease, in particular, are associated with substantial excess mortality in persons with chronic hepatitis C.
引用
收藏
页码:1957 / +
页数:15
相关论文
共 39 条
[1]   Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection [J].
Afdhal, Nezam ;
Zeuzem, Stefan ;
Kwo, Paul ;
Chojkier, Mario ;
Gitlin, Norman ;
Puoti, Massimo ;
Romero-Gomez, Manuel ;
Zarski, Jean-Pierre ;
Agarwal, Kosh ;
Buggisch, Peter ;
Foster, Graham R. ;
Braeu, Norbert ;
Buti, Maria ;
Jacobson, Ira M. ;
Subramanian, G. Mani ;
Ding, Xiao ;
Mo, Hongmei ;
Yang, Jenny C. ;
Pang, Phillip S. ;
Symonds, William T. ;
McHutchison, John G. ;
Muir, Andrew J. ;
Mangia, Alessandra ;
Marcellin, Patrick .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20) :1889-1898
[2]   Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection [J].
Afdhal, Nezam ;
Reddy, K. Rajender ;
Nelson, David R. ;
Lawitz, Eric ;
Gordon, Stuart C. ;
Schiff, Eugene ;
Nahass, Ronald ;
Ghalib, Reem ;
Gitlin, Norman ;
Herring, Robert ;
Lalezari, Jacob ;
Younes, Ziad H. ;
Pockros, Paul J. ;
Di Bisceglie, Adrian M. ;
Arora, Sanjeev ;
Subramanian, G. Mani ;
Zhu, Yanni ;
Dvory-Sobol, Hadas ;
Yang, Jenny C. ;
Pang, Phillip S. ;
Symonds, William T. ;
McHutchison, John G. ;
Muir, Andrew J. ;
Sulkowski, Mark ;
Kwo, Paul .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (16) :1483-1493
[3]  
[Anonymous], 2013, VITAL HLTH STAT SERI
[4]   The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 [J].
Armstrong, Gregory L. ;
Wasley, Annemarie ;
Simard, Edgar P. ;
McQuillan, Geraldine M. ;
Kuhnert, Wendi L. ;
Alter, Miriam J. .
ANNALS OF INTERNAL MEDICINE, 2006, 144 (10) :705-714
[5]   Steatosis in chronic hepatitis C: Why does it really matter? [J].
Asselah, T ;
Rubbia-Brandt, L ;
Marcellin, P ;
Negro, F .
GUT, 2006, 55 (01) :123-130
[6]   Prevalence and Treatment of Chronic Hepatitis C Virus Infection in the US Department of Veterans Affairs [J].
Beste, Lauren A. ;
Ioannou, George N. .
EPIDEMIOLOGIC REVIEWS, 2015, 37 (01) :131-143
[7]  
Centers for Disease Control and Prevention, 2016, HLTH REL QUAL LIF HL
[8]   Impact of obesity on treatment of chronic hepatitis C [J].
Charlton, Michael R. ;
Pockros, Paul J. ;
Harrison, Stephen A. .
HEPATOLOGY, 2006, 43 (06) :1177-1186
[9]   Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010 [J].
Denniston, Maxine M. ;
Jiles, Ruth B. ;
Drobeniuc, Jan ;
Klevens, R. Monina ;
Ward, John W. ;
McQuillan, Geraldine M. ;
Holmberg, Scott D. .
ANNALS OF INTERNAL MEDICINE, 2014, 160 (05) :293-+
[10]   The changing epidemiology of hepatitis C virus infection in the United States: National health and nutrition examination survey 2001 through 2010 [J].
Ditah, Ivo ;
Ditah, Fausta ;
Devaki, Pardha ;
Ewelukwa, Oforbuike ;
Ditah, Chobufo ;
Njei, Basile ;
Luma, Henry N. ;
Charlton, Michael .
JOURNAL OF HEPATOLOGY, 2014, 60 (04) :691-698